First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in accordance with progressive β cell failure a...
Glimepiride is indicated for the management of type 2 diabetes in adults as an adjunct to diet and exercise to improve glycemic control as monotherapy.
...
Investigational Site Number 414001, Kuwait, Kuwait
Investigational Site Number 642005, Iasi, Romania
Investigational Site Number 642010, Oradea, Romania
Centro Universitario de Ciencias de la Salud. Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
Medical Dept. 2, Grosshadern, University Munich, Munich, Germany
Sanofi-Aventis Administrative Office, Shanghai, China
Korea University Guro Hospital, Seoul, Korea, Republic of
Kyung hee University Medical Center, Seoul, Korea, Republic of
Hanyang University Medical Center, Guri-si, Kyunggi-do, Korea, Republic of
Ppd Development, Austin, Texas, United States
GSK Investigational Site, London, United Kingdom
GSK Investigational Site, London, United Kingdom
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.